Macrophages play a complex role in cancer. They can help eliminate tumors (M1) but can also be "tricked" by cancer cells to promote tumor growth (M2).
Enlivex's (ENLV) approach aims to reprogram tumor-associated macrophages (TAMs) from a tumor-promoting (M2) state to an anti-tumor (M1) state, potentially enhancing the body's natural ability to fight cancer.
This reprogramming could potentially complement existing cancer therapies like surgery, radiation, and chemotherapy.
